Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

被引：57

作者：

Alva, A. ^{[1
]}

Csoszi, T. ^{[2
]}

Ozguroglu, M. ^{[3
]}

Matsubara, N. ^{[4
]}

Geczi, L. ^{[5
]}

Cheng, S. Y-S. ^{[6
]}

Fradet, Y. ^{[7
]}

Oudard, S. ^{[8
]}

Vulsteke, C. ^{[9
]}

Morales Barrera, R. ^{[10
]}

Flechon, A. ^{[11
]}

Gunduz, S. ^{[12
]}

Loriot, Y. ^{[13
]}

Rodriguez-Vida, A. ^{[14
]}

Mamtani, R. ^{[15
]}

Yu, E. Y. ^{[16
]}

Nam, K. ^{[17
]}

Imai, K. ^{[18
]}

Moreno, B. H. ^{[19
]}

Powles, T. B. ^{[20
]}

机构：

[1] Univ Michigan, Hematol Oncol, Ann Arbor, MI 48109 USA

[2] Hetenyi G Korhaz Onkol Kozpont, Oncol, Szolnok, Hungary

[3] Istanbul Univ Cerrahpasa, Med Oncol, Cerrahpasa Sch Med, Istanbul, Turkey

[4] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[5] Natl Inst Oncol Hungary, Med Oncol, Budapest, Hungary

[6] Sunnybrook Odette Canc Ctr, Oncol, Toronto, ON, Canada

[7] Univ Laval, CHU Quebec, Surg Urol, Quebec City, PQ, Canada

[8] Hop European George Pompidou, Immunotherapie & Traitement Antiangiogen Pathol C, Paris, France

[9] Ctr Oncol Res CORE, Antwerp, Belgium

[10] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[11] Ctr Leon Berard, Dept Med Oncol, Rhones Alpes, France

[12] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkey

[13] Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Hosp del Mar, Dept Med Oncol, Barcelona, Spain

[15] Univ Penn, Abramson Canc Ctr, Hematol Oncol, Philadelphia, PA 19104 USA

[16] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[17] Merck & Co Inc, Stat, Kenilworth, NJ USA

[18] Merck & Co Inc, Clin Res Oncol Dept, Kenilworth, NJ USA

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Queen Mary Univ London, Barts Canc Inst, Dept Med Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA23

引用

页码：S1155 / S1155

页数：1